Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Head & Neck 1Gynecologic 1Breast 1

Conditions

Pancreatic Neoplasms 11Neoplasms 4Stomach Neoplasms 2Small Cell Lung Carcinoma 2Metastatic Pancreatic Adenocarcinoma 2Colorectal Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumor 1Refractory Solid Tumors 1Pancreatic cancer, adult 1Pancreatic Diseases 1Pancreatic Cancer Non-resectable 1Ovarian Neoplasms 1Neoplasm Metastasis 1Metastatic Adenocarcinoma of the Pancreas 1Malignant Tumor of Pancreas Metastatic to Liver 1Head and Neck Neoplasms 1Gallbladder Neoplasms 1Endocrine Gland Neoplasms 1Digestive System Neoplasms 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Pancreatic Ductal 1Carcinoma, Islet Cell 1Biliary Tract Neoplasms 1Advanced Solid Tumors 1Advanced Pancreatic Cancer 1Advanced Esophageal Squamous Cell Cancer 1Advanced Breast Cancer 1Adenoma, Islet Cell 1

Interventions

Capecitabine 77pembrolizumab 70Oxaliplatin 68Cisplatin 56Fluorouracil 52Paclitaxel 41Trastuzumab 37Nivolumab 35Leucovorin 27Docetaxel 27Irinotecan 22Ramucirumab 20Gemcitabine 15Bevacizumab 15S 1 (combination) 14Carboplatin 13atezolizumab 12apatinib 12fludarabine 11Cyclophosphamide 11tislelizumab 10Drug Therapy 10Injections 8130-nm albumin-bound paclitaxel 8trastuzumab deruxtecan 7durvalumab 7Ipilimumab 7Folfox protocol 7Albumin-Bound Paclitaxel 7titanium silicide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Stomach Neoplasms × irinotecan sucrosofate × Clear all
NCT06219941 2026-02-12

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

AstraZeneca

Phase 2 Recruiting
224 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Stomach Neoplasms

NCT01770353 2019-11-27

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Ipsen

Phase 1 Completed
45 enrolled 33 charts
BreastGastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡